Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Related ACHNAfter-Hours Movers Led By Bob Evans, Bazaarvoice And Smith & Wesson On TuesdayTop 5 Biotech Stocks That The Smart Money Doesn’t LikeAchillion Pharma updates guidance after Q4 results(Seeking Alpha)Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at […]
View photo.Deutsche Bank on Thursday named its top Small-Cap Biotech picks for 2015. The top picks were selected because they were either a disruptive technology, a rare or orphan disease market, an unmet need market or a stock with a big-time catalyst.Here is what to watch for in Deutsche’s top picks.
PTC Therapeutics, Inc. (NASDAQ: PTCT)
Deutsche highlighted PTC Therapeutics as its […]
View gallery.A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States.
HCV Forerunners Gilead And AbbVie
Morgan Stanley projects that Gilead Sciences, Inc.’s (NASDAQ: GILD) Harvoni and Sovaldi […]
